Skip to main content

Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding.

Publication ,  Journal Article
Wang, TY; Xiao, L; Alexander, KP; Rao, SV; Kosiborod, MN; Rumsfeld, JS; Spertus, JA; Peterson, ED
Published in: Circulation
November 18, 2008

BACKGROUND: Bleeding among patients with acute myocardial infarction (AMI) is associated with worse long-term outcomes. Although the mechanism underlying this association is unclear, a potential explanation is that withholding antiplatelet therapies long beyond resolution of the bleeding event may contribute to recurrent events. METHODS AND RESULTS: We examined medication use at discharge, 1, 6, and 12 months after AMI among 2498 patients in the Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER) registry. Bleeding was defined as non-coronary artery bypass graft-related Thrombolysis of Myocardial Infarction major/minor bleeding or transfusion among patients with baseline hematocrit > or =28%. Logistic regression was used to evaluate the association between bleeding during the index AMI hospitalization and medication use. In-hospital bleeding occurred in 301 patients (12%) with AMI. Patients with in-hospital bleeding were less likely to be discharged on aspirin or thienopyridine (adjusted odds ratio=0.45; 95% CI, 0.31 to 0.64; and odds ratio=0.62; 95% CI, 0.42 to 0.91, respectively). At 1 month after discharge, although patients with in-hospital bleeding remained significantly less likely to receive aspirin (odds ratio=0.68; 95% CI, 0.50 to 0.92), use of thienopyridines in the 2 groups started to become similar. By 1 year, antiplatelet therapy use was similar among patients with and without bleeding. Postdischarge cardiology follow-up was associated with greater antiplatelet therapy use than either primary care or no clinical follow-up. CONCLUSIONS: Patients whose index AMI is complicated by bleeding are less likely to be treated with antiplatelet therapies during the first 6 months after discharge. Early reassessment of antiplatelet eligibility may represent an opportunity to reduce the long-term risk of adverse outcomes associated with bleeding.

Duke Scholars

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

November 18, 2008

Volume

118

Issue

21

Start / End Page

2139 / 2145

Location

United States

Related Subject Headings

  • Regression Analysis
  • Registries
  • Pyridines
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
  • Hospitals
  • Hemorrhage
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wang, T. Y., Xiao, L., Alexander, K. P., Rao, S. V., Kosiborod, M. N., Rumsfeld, J. S., … Peterson, E. D. (2008). Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation, 118(21), 2139–2145. https://doi.org/10.1161/CIRCULATIONAHA.108.787143

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

November 18, 2008

Volume

118

Issue

21

Start / End Page

2139 / 2145

Location

United States

Related Subject Headings

  • Regression Analysis
  • Registries
  • Pyridines
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
  • Hospitals
  • Hemorrhage